Trial reportJournal of gastroenterology2026
A phase I/II clinical trial of neoadjuvant docetaxel/oxaliplatin/S‑1 (DOS) combination therapy for gastroesophageal junction adenocarcinoma.
Trial report in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastroesophageal junction (GEJ) adenocarcinoma is aggressive with poor prognosis. Perioperative chemotherapy has become standard, but the optimal regimen remains uncertain. DOS has shown activity in gastric cancer but has not been prospectively assessed in GEJ adenocarcinoma. This study represents the first prospective trial of DOS as neoadjuvant chemotherapy in patients with resectable GEJ adenocarcinoma.
methodsThis single-arm, single-center phase I/II trial (UMIN000022210) enrolled patients with cT3-4aN0-3M0 GEJ adenocarcinoma. The phase I part established the recommended docetaxel dose (60 mg/m
resultsForty-three patients were enrolled; 37 received DOS at the recommended dose. Of these, 83.8% completed all planned cycles. Grade ≥ 3 neutropenia occurred in 81.1%, and febrile neutropenia in 18.9%. The R0 resection rate was 94.6% (35/37; 95% CI, 81.8-99.3). Major postoperative complications occurred in 11.4%, with no operative mortality. Major pathological response was achieved in 40.5% of patients, including a pathological complete response rate of 5.4%. At 3 years, overall survival and relapse-free survival were 84.9% and 64.5%, respectively. Patients downstaged to ypStage 0 or IA had significantly better relapse-free survival than others.
conclusionsNeoadjuvant DOS chemotherapy showed high R0 resection rates, acceptable toxicity, and favorable survival in resectable GEJ adenocarcinoma, supporting its potential as a treatment option. These findings provide important evidence from East Asia, where S-1-based regimens remain widely used, and complement Western data on perioperative FLOT therapy.
Indexed as
Identifiers
41721869What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.